IL82471A - Aids virus related peptides, antibodies to the peptides, vaccines, passive and active immunization against aids virus and diagnostic test for the serological detection of the aids virus - Google Patents

Aids virus related peptides, antibodies to the peptides, vaccines, passive and active immunization against aids virus and diagnostic test for the serological detection of the aids virus

Info

Publication number
IL82471A
IL82471A IL82471A IL8247187A IL82471A IL 82471 A IL82471 A IL 82471A IL 82471 A IL82471 A IL 82471A IL 8247187 A IL8247187 A IL 8247187A IL 82471 A IL82471 A IL 82471A
Authority
IL
Israel
Prior art keywords
aids virus
aids
alpha
antisera
peptides
Prior art date
Application number
IL82471A
Other languages
English (en)
Other versions
IL82471A0 (en
Original Assignee
Viral Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viral Technologies Inc filed Critical Viral Technologies Inc
Publication of IL82471A0 publication Critical patent/IL82471A0/xx
Publication of IL82471A publication Critical patent/IL82471A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036Retroviridae, e.g. leukemia viruses
    • C07K16/1045Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1054Lentiviridae, e.g. HIV, FIV, SIV gag-pol, e.g. p17, p24
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/14011Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16211Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • AIDS & HIV (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL82471A 1986-05-19 1987-05-10 Aids virus related peptides, antibodies to the peptides, vaccines, passive and active immunization against aids virus and diagnostic test for the serological detection of the aids virus IL82471A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86459986A 1986-05-19 1986-05-19

Publications (2)

Publication Number Publication Date
IL82471A0 IL82471A0 (en) 1987-11-30
IL82471A true IL82471A (en) 1993-02-21

Family

ID=25343634

Family Applications (1)

Application Number Title Priority Date Filing Date
IL82471A IL82471A (en) 1986-05-19 1987-05-10 Aids virus related peptides, antibodies to the peptides, vaccines, passive and active immunization against aids virus and diagnostic test for the serological detection of the aids virus

Country Status (17)

Country Link
EP (1) EP0246829B1 (xx)
JP (3) JPH089636B2 (xx)
KR (1) KR910002690B1 (xx)
CN (1) CN87103568A (xx)
AT (1) ATE100469T1 (xx)
AU (1) AU606595B2 (xx)
DE (1) DE3788822T2 (xx)
DK (1) DK173040B1 (xx)
ES (1) ES2061495T3 (xx)
GB (1) GB2190679B (xx)
IE (1) IE60274B1 (xx)
IL (1) IL82471A (xx)
IN (1) IN167198B (xx)
MX (1) MX167236B (xx)
NZ (1) NZ220200A (xx)
PH (1) PH26239A (xx)
ZA (1) ZA873215B (xx)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1219232A (en) * 1983-08-17 1987-03-17 Richard A. Lerner Polypeptide-induced monoclonal receptors to protein ligands
US4863730A (en) * 1986-03-21 1989-09-05 Cenfold Holdings, S.A. Immunotherapy for AIDS patients
EP0346022B1 (en) * 1988-06-10 1996-02-14 United Biomedical, Inc. Peptide fragments of HIV
US5219725A (en) 1988-12-05 1993-06-15 Idexx Laboratories Incorporated Monoclonal antibodies to feline-t-lymphotropic lentivirus
EP0456753B1 (en) * 1989-02-01 1994-05-04 E.I. Du Pont De Nemours And Company HIV p17 ASSAYS FOR MONITORING DEVELOPMENT OF AIDS
JP3058685B2 (ja) * 1989-05-08 2000-07-04 アイデックス ラボラトリーズ インコーポレーテッド ネコt細胞リンパトロピック レンチウィルスのポリペプチド
NZ235538A (en) * 1989-10-12 1992-06-25 Viral Technologies Inc Peptides immunoreactive with antibodies to hiv p17; carrier-bound peptides, vaccines, immunoassay and a method for forming antibody enriched sera
DE4106686A1 (de) * 1991-03-02 1992-09-03 Daimler Benz Ag Verriegelungsanordnung
FR2734281B1 (fr) * 1995-05-18 1997-07-25 Commissariat Energie Atomique Fragments d'acide nucleique derives du genome du virus vih-1, peptides correspondants et leurs applications en tant que reactifs d'evaluation du risque de transmission materno-foetale du vih-1
IL128412A0 (en) 1996-08-09 2000-01-31 Viral Technologies Inc Hiv p-17 peptide fragment, compositions containing and methods for producing and using same
US6093400A (en) * 1996-08-09 2000-07-25 Cel Sci Corporation Modified HGP-30 peptides, conjugates, compositions and methods of use
US6818392B2 (en) 2000-12-06 2004-11-16 Abbott Laboratories Monoclonal antibodies to human immunodeficiency virus and uses thereof
EP1217719B1 (en) 2000-12-21 2010-11-17 Semiconductor Components Industries, LLC Method and apparatus for reducing audible noise in a power supply transformer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4264571A (en) * 1979-01-22 1981-04-28 George Washington University Radioimmunoassay of thymosin α1
DE2919592A1 (de) * 1979-05-15 1981-01-15 Max Planck Gesellschaft Verfahren zur herstellung von thymosin- alpha 1 und derivaten davon
US4339427A (en) * 1980-04-14 1982-07-13 Hoffmann-La Roche Inc. Radioimmunoassay of thymosinα
US4517119A (en) * 1983-04-04 1985-05-14 Hoffmann-La Roche Inc. Synthesis of thymosin α1
US4504415A (en) * 1983-04-04 1985-03-12 Hoffman-La Roche Inc. Synthesis of thymosin α1 and desacetyl thymosin α1

Also Published As

Publication number Publication date
GB2190679B (en) 1991-02-20
JPS6327498A (ja) 1988-02-05
IN167198B (xx) 1990-09-15
CN87103568A (zh) 1988-01-27
NZ220200A (en) 1990-08-28
DE3788822D1 (de) 1994-03-03
KR870011154A (ko) 1987-12-21
EP0246829A2 (en) 1987-11-25
DK173040B1 (da) 1999-11-29
AU606595B2 (en) 1991-02-14
IE60274B1 (en) 1994-06-29
JPH083200A (ja) 1996-01-09
DK245287A (da) 1987-11-20
DE3788822T2 (de) 1994-07-28
ES2061495T3 (es) 1994-12-16
MX167236B (es) 1993-03-11
PH26239A (en) 1992-04-01
IE871289L (en) 1987-11-19
ATE100469T1 (de) 1994-02-15
GB8711567D0 (en) 1987-06-17
JPH089636B2 (ja) 1996-01-31
KR910002690B1 (ko) 1991-05-03
IL82471A0 (en) 1987-11-30
AU7313587A (en) 1987-11-26
DK245287D0 (da) 1987-05-14
EP0246829A3 (en) 1989-08-09
ZA873215B (en) 1987-10-28
EP0246829B1 (en) 1994-01-19
GB2190679A (en) 1987-11-25
JPH0925300A (ja) 1997-01-28
JP2598245B2 (ja) 1997-04-09

Similar Documents

Publication Publication Date Title
Nara et al. Persistent infection of chimpanzees with human immunodeficiency virus: serological responses and properties of reisolated viruses
Jiang et al. Enhancement of human immunodeficiency virus type 1 infection by antisera to peptides from the envelope glycoproteins gp120/gp41.
Schable et al. Sensitivity of United States HIV antibody tests for detection of HIV-1 group O infections
CA1280363C (en) Peptide composition and method for the detection of antibodies to htlv-iii
EP0246829A3 (en) Htlv-iii virus related peptides, antibodies to the peptides, vaccines, passive and active immunization against aids virus and diagnostic test for the serological detection of the aids virus
EP0269712A1 (en) Peptides involved in the pathogenesis of hiv infection
Haynes et al. Induction of HIVMN neutralizing antibodies in primates using a prime-boost regimen of hybrid synthetic gp120 envelope peptides.
Kovacs et al. Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.
FI101797B (fi) STLV-III-virukseen liittyvät polypeptidit, diagnostiset järjestelmät j a määritysmenetelmät
US5017688A (en) Peptides involved in the pathogenesis of HIV infection
Lee et al. Epstein‐Barr virus isolates with the major HLA B35. 01‐restricted cytotoxic T lymphocyte epitope are prevalent in a highly B35. 01‐positive African population
BÖTTIGER et al. Cross-neutralizing antibodies against HIV-1 (HTLV-IIIB and HTLV-IIIRF) and HIV-2 (SBL-6669 and a new isolate SBL-K135)
US6093400A (en) Modified HGP-30 peptides, conjugates, compositions and methods of use
Krook et al. HTLV-II among injecting drug users in Stockholm
Kanner et al. Human retroviral env and gag polypeptides: serologic assays to measure infection.
DK0426314T3 (da) HIV-relaterede peptider
RU96116005A (ru) Штамм hominis immunodeficiti virus (hiv-i) вич-i/россия/гм-12-95 (ru1295) субтипа в для диагностических и вакцинных препаратов
US4943627A (en) Peptides involved in the pathogenesis of HIV infection
Palker et al. Purification of envelope glycoproteins of human T cell lymphotropic virus type I (HTLV-I) by affinity chromatography
KR930008448B1 (ko) T-4수용체에 대한 결합을 억제하며, 면역원으로서 작용하는 소형 펩티드
US5681696A (en) Synthetic peptide compositions with immunoreactivities to antibodies to HTLV
HARAOA et al. Serological differences between human T-lymphotropic virus type-I (HTLV-I) and HTLV-III/LAV
EP0323424A3 (en) Peptide corresponding to hiv-env 583-599, and analogs thereof and applications of the peptides
TH9844EX (th) เพพไทด์ที่สัมพันธุ์ hiv
TH9844A (th) เพพไทด์ที่สัมพันธุ์ hiv

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees